Related references
Note: Only part of the references are listed.Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Seth E. Karol et al.
LANCET ONCOLOGY (2020)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Ernesto Diaz-Flores et al.
CANCER RESEARCH (2019)
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
Amanda McBride et al.
FRONTIERS IN ONCOLOGY (2019)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Wendy Stock et al.
BLOOD (2019)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Zhaohui Gu et al.
NATURE GENETICS (2019)
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia
N. Toft et al.
LEUKEMIA (2018)
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen
Trevor N. Christ et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain et al.
BLOOD (2017)
Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma
Tapan M. Kadia et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic Factors and Outcomes of Adult Lymphoblastic Lymphoma in the United States
Mohamed Abd El-Fattah
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
Jeremy Ryan et al.
BIOLOGICAL CHEMISTRY (2016)
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Seong Lin Khaw et al.
BLOOD (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia
Jessica T. Leonard et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Sarah E. Alford et al.
CANCER RESEARCH (2015)
Genomics in acute lymphoblastic leukaemia: insights and treatment implications
Kathryn G. Roberts et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Santi Suryani et al.
CLINICAL CANCER RESEARCH (2014)
Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
Dan Douer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Triona Ni Chonghaile et al.
CANCER DISCOVERY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Quality control and preprocessing of metagenomic datasets
Robert Schmieder et al.
BIOINFORMATICS (2011)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
Integrative genomics viewer
James T. Robinson et al.
NATURE BIOTECHNOLOGY (2011)
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Richard H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
Laura M. High et al.
MOLECULAR PHARMACOLOGY (2010)
Mcl-1 is a potential therapeutic target in multiple types of cancer
C. Akgul
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group
Birgit Burkhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Elaine Coustan-Smith et al.
LANCET ONCOLOGY (2009)
Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy
Susan O'Brien et al.
CANCER (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
Richard Lock et al.
PEDIATRIC BLOOD & CANCER (2008)
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Victoria Del Gaizo Moore et al.
BLOOD (2008)
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Min H. Kang et al.
BLOOD (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins
M Konopleva et al.
LEUKEMIA (2002)
The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis
P Schneider et al.
LEUKEMIA (2001)
Share Paper
